Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Figure 3

Change in tumor size by arm (a) and serum proteomic classifier (b). The log of the ratio of the tumor size at the first evaluation on treatment (T1) to the baseline tumor size (T0) is plotted for each subject. The top red dashed line marks RECIST criteria for progressive disease at the time of the first CT scan, any values at or below the bottom dashed red line meet RECIST criteria for response, and those meeting criteria for stable disease lie in between the two dashed lines. Circles represent actual measured values, while triangle symbols indicate those subjects with brain MRIs confirming new metastases at the first evaluation and therefore equated with the change in tumor size of the worst progressor. The early death in Arm B was assigned a T1/T0 value of 2.5 (log(T1/T0) = 0.92).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us